erostratus Yes MCC is showing very promising results but as of Jan2014 IMO there were not enough persons enrolled and tested for a Peer Review as statistically significant. The 15 intended enrollment would not be met until 2H2014.
IMO both presentations, ASGCT and ASCO, can be for the Melanoma Clinical Trials P1/P2 with a big difference though as to what would be presented at ASGCT vs ASCO
At ASGCT, Dr. Heller would present in a summary all of the existing Public information ALREADY DISCLOSED by $ONCS and describe the Gene/Cell therapy theory as related to the Protein IL-12 and the EP enhancement as creation of the induced immunogenicity of the Melanoma cancer tumor and the role of (1) EP and (2) IL-12.
At ASCO, Dr. Daud, as the $ONCS principal investigator, or Dr. Pierce as $ONCS CMO, would present in a summary all of the new Non-Public latest Oncology information NEVER DISCLOSED by $ONCS TLD for the P1 and P2 latest historical statistical data as of Jan 2014 for Peer Review and Judgement evaluation.
This type of two different presentations regarding the same therapy for the same disease has been done before by Pharmas within a short time span of a few weeks or a few months apart. The first a general summary of past public information and the 2nd Peer Review TLD new data. The 2nd Peer Review can be live presentation or submittal to a Peer Review Journal.
JMHO
News 
Market Data 
Discover 
